Potential clinical applications of PET/MR imaging in neurodegenerative diseases

Journal of Nuclear Medicine

Volumn 55, Issue 6 SUPPL. 2, 2014, Pages

  Drzezga, Alexander ^a   Barthel, Henryk ^b   Minoshima, Satoshi ^c   Sabri, Osama ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Dementia; Hybrid imaging; MR PET; Neurodegeneration; PET MR

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ARTIFACT REDUCTION; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN SIZE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HEAD MOVEMENT; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPIN LABELING; WORKFLOW;

EID: 84903173774     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129254     Document Type: Article

References (71)

1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783.
2. Thies W, Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013;9:208-245.
3. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732-1740.
4. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-128.
5. Scheltens PH. Structural neuroimaging of Alzheimer's disease and other dementias. Aging (Milano). 2001;13:203-209.
6. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21-43.
7. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci. 1999;354:1155-1163. (Pubitemid 29400898)
8. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
9. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
10. Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. March 20, 2014 [Epub ahead of print].
11. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
12. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
13. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459-465. (Pubitemid 351499385)
14. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
15. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
16. Eggers C, Szelies B, Bauer B, et al. Imaging of acetylcholine esterase activity in brainstem nuclei involved in regulation of sleep and wakefulness. Eur J Neurol. 2007;14:690-693. (Pubitemid 46849046)
17. Yanase D, Matsunari I, Yajima K, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging. 2005;32:794-805. (Pubitemid 41125422)
18. Sattler B, Jochimsen T, Barthel H, et al. Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. MAGMA. 2013;26:159-171.
19. Chen J, Yao J, Thomasson D. Automatic determination of arterial input function for dynamic contrast enhanced MRI in tumor assessment. Med Image Comput Comput Assist Interv. 2008;11:594-601.
20. Chen K, Chen X, Renaut R, et al. Characterization of the image-derived carotid artery input function using independent component analysis for the quantitation of 18F-fluorodeoxyglucose positron emission tomography images. Phys Med Biol. 2007;52:7055-7071. (Pubitemid 350150631)
21. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
22. Catana C, Benner T, van der Kouwe A, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154-161.
23. Musiek ES, Chen Y, Korczykowski M, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement. 2012;8:51-59.
24. Andersen FL, Ladefoged CN, Beyer T, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206-216.
25. 18F-FDG brain imaging in patients examined for suspected dementia. J Nucl Med. In press.
26. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl. 3):14-22.
27. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38:1688-1693. (Pubitemid 18265030)
28. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746. (Pubitemid 47058377)
29. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
30. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67-77.
31. Whitwell JL, Jack CR Jr. Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping. Top Magn Reson Imaging. 2005;16:409-425. (Pubitemid 44699399)
32. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol. 2009;30:404-410.
33. Kawachi T, Ishii K, Sakamoto S, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006;33:801-809. (Pubitemid 43979688)
34. 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med. 2007;48:1961-1970.
35. Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191-199.
36. Jack CR Jr, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68:1526-1535.
37. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004;14:721-730. (Pubitemid 38856947)
38. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet. 2004;363:392-394. (Pubitemid 38169550)
39. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17:1236-1248.
40. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6-16.
41. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365. (Pubitemid 32848738)
42. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127. (Pubitemid 34041597)
43. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576-1582.
44. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
45. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
46. 18F- flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319-329.
47. 11C-PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
48. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-2844. (Pubitemid 350033975)
49. Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688-1697.
50. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76:1085-1090.
51. 11C-PIB PET study. Neurology. 2009;73:754-760.
52. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104-114.
53. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-333.
54. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry. July 3, 2013 [Epub ahead of print].
55. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8:389-398.
56. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034-2042.
57. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
58. Perneczky R, Drzezga A, Diehl-Schmid J, et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry. 2006;77:1060-1063. (Pubitemid 44338530)
59. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
60. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11 C-PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665-680. (Pubitemid 351294719)
61. Frisoni GB, Bocchetta M, Chételat G, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487-500.
62. 18F-FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2013;40:1567-1572.
63. Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS ONE. 2013;8:e66877.
64. Zhang D, Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS ONE. 2012;7:e33182.
65. Jack CR Jr,Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336-3348.
66. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
67. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73:472-480.
68. Dukart J, Mueller K, Horstmann A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS ONE. 2011;6:e18111.
69. Cha YH, Jog MA, Kim YC, Chakrapani S, Kraman SM, Wang DJ. Regional correlation between resting state FDG PET and pCASL perfusion MRI. J Cereb Blood Flow Metab. 2013;33:1909-1914.
70. 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393-400.
71. 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173-179.